HIV / AIDS

The therapy would be the first capsid inhibitor and the only HIV treatment option administered every 6 months.

More treatment options and modalities are now available for patients.

Rates of HIV diagnoses among adults and adolescents is higher in southern states, and organizations are looking to reverse this trend and address inequities.

Study of biomarkers of epigenetic aging in patients with HIV finds antiretroviral therapy partially reverses the accelerated aging associated with the infection.

A discussion on issues surrounding the treatment of HIV with Melissa Badowski, PharmD, MPH.

As the HIV population ages, a variety of health challenges may arise that typically happen in populations without chronic conditions.

People living with HIV/AIDS were found to have 24% higher risk of infection with SARS-CoV-2.

With its mRNA COVID-19 vaccine authorized, the company is employing the technology to take aim at a variety of pathogens.

A new study assessed the life expectancy gains for those adults with HIV and being treated with antiretroviral therapy living in Latin America and the Caribbean.

The new report highlights the broad disparities in HIV health among different populations, with Black transgender women facing the highest rates of HIV infection.

This is our inaugural segment for our new video series, 1 Big Question, where we ask the medical community a question about a significant infectious disease topic and get feedback from them.

The prevalence of this disease in this patient population is much higher than in the general public.

Investigators incorporated universal HIV screening into COVID-19 testing at a Chicago hospital emergency department (ED).

The ATLAS 2M study results showed non-inferiority in 2-month dosing compared to 1-month dosing for the cabotegravir and rilpivirine long-acting injectable.

A recent study looked at the racial disparities amongst people living with HIV and COVID-19 positivity rates.

2020 forced clinicians and people with HIV (PWH) to adapt to the COVID-19 pandemic. While initially it had an immediate impact on patient care, new solutions and strategies were created to ensure health care was delivered to those who needed it.

Two randomized trials involved more than 4500 patients to determine the efficacy of a broadly neutralizing antibody in blocking acquisition of HIV infection.

A new cohort assessment evidences a disparity in weight-related outcomes with the ART regimens at 18 months.

The phase 2b-3 trial analyzing the efficacy of the ALVAC–gp120 regimen showed that it did not prevent an HIV-1 infection among the participants in the study at 24 months.

Long-acting injectables for latent and active tuberculous (TB) might be a treatment option in the future and could open up the door to possibly bundling HIV and TB care together.

A comparative study of same-day and seven-day TB test results show there is little difference in HIV treatment adherence or outcomes at 48 weeks.

Phase 1/2 trial results showed the immunomodulary vaccine regimen could induce significant T-cell response in patients with HIV.

Managing mental health in adults living with HIV is paramount during the COVID-19 pandemic.

Index testing declined in countries including Malawi, Lesotho and Zimbabwe.

Deep learning models identified the largest differences in resting state network topology occurred.

The prognostic proteins identified can serve as the basis of future pathway and network analyses.

Dapivrine (DPV) was studied in 1-month and 3-month durations.

During the pandemic, reduced HIV testing led to concerns about getting people diagnosed and on antiretroviral therapy (ART), and achieving viral suppression (VS).

ViiV Healthcare’s investigational therapy, GSK’254, demonstrated antiviral activity, safety, and tolerability in its phase 2a proof-of-concept findings.

With the highest HIV incidence rate in this part of the country, the need to get people from diagnosis to timely antiretroviral therapy (ART) remains an urgent need.